top of page

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn’s Disease (VIVID-1)

Dr. Zheng is the principal investigator of an Institutional Review Board (IRB)-approved Phase III clinical trial of mirikizumab, an IL-23 inhibitor, for patients with Crohn’s disease. Do you have or know someone that has

  • Moderately to severely active Crohn’s Disease

  • Inadequate response, loss of response or intolerance to either conventional or biologic medications for Crohn’s


As study participants, you may receive access (free of charge) to this cutting-edge therapy as well as free study-related medical care and compensation for time. 


As physicians, we want to offer our patients the best care available, but currently approved therapies are not always sufficient or insurance restrictions like step therapy force us to prescribe a suboptimal drug. Clinical research can bridge that gap while also advancing medical knowledge and improving the future of care.

To refer patients for this Crohn’s study or learn more, please contact Our study coordinator, Sofhia Samimi at


Thank you for any support you may provide with giving IBD patients new care options.


Little Girl Praying

Fatty Liver (NAFLD/NASH) Clinical Trial

Please check back soon

bottom of page